8 Papers
34 Citations
Pingna Deng is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 5, co-authored 8 publications. Previous affiliations of Pingna Deng include Harvard University.
Chat about Author
Papers
Passenger deletions generate therapeutic vulnerabilities in cancer
Florian L. Muller,Simona Colla,Elisa Aquilanti,Veronica E. Manzo,Giannicola Genovese,Jaclyn Lee,Daniel Eisenson,Rujuta Narurkar,Pingna Deng,Pingna Deng,Luigi Nezi,Michelle A. Lee,Michelle A. Lee,Baoli Hu,Baoli Hu,Jian Hu,Ergun Sahin,Ergun Sahin,Derrick Sek Tong Ong,Eliot Fletcher-Sananikone,Dennis Ho,Dennis Ho,Lawrence N. Kwong,Cameron Brennan,Cameron Brennan,Y. Alan Wang,Lynda Chin,Lynda Chin,Ronald A. DePinho +28 more
TL;DR: It is shown that short-hairpin-RNA-mediated silencing of ENO2 selectively inhibits growth, survival and the tumorigenic potential of ENN1-deleted GBM cells, and that the enolase inhibitor phosphonoacetohydroxamate is selectively toxic to ENO1- deleted G BM cells relative to ENo1-intact GBM Cells or normal astrocytes.
Opposing roles of TGFβ and BMP signaling in prostate cancer development.
Xin Lu,Xin Lu,Xin Lu,Eun-Jung Jin,Eun-Jung Jin,Xi Cheng,Xi Cheng,Shan Feng,Shan Feng,Xiaoying Shang,Pingna Deng,Shan Jiang,Qing Chang,Sharif Rahmy,Seema Chaudhary,Xuemin Lu,Ren Zhao,Y. Alan Wang,Ronald A. DePinho +18 more
TL;DR: It is demonstrated that the molecular actions of TGFBR2 result in both SMAD4-dependent constraint of proliferation and SMAD1-independent activation of apoptosis, and BMPR2 deletion extended survival relative to Pten deletion alone, establishing its promoting role in BMP6-driven prostate cancer progression.
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.
Xin Lu,Xin Lu,Xin Lu,Xiaolu Pan,Chang-Jiun Wu,Di Zhao,Shan Feng,Yong Zang,Rumi Lee,Sunada Khadka,Samirkumar B. Amin,Eun-Jung Jin,Xiaoying Shang,Pingna Deng,Yanting Luo,William R. Morgenlander,Jacqueline Weinrich,Xuemin Lu,Shan Jiang,Qing Chang,Nora M. Navone,Patricia Troncoso,Ronald A. DePinho,Y. Alan Wang +23 more
TL;DR: Results indicate that PYGO2 functions as a driver oncogene in the 1q21.3 amplicon and may serve as a potential prognostic biomarker and therapeutic target for metastatic prostate cancer.
Opposing roles of TGFβ and BMP signaling in prostate cancer development
Xin Lu,Xin Lu,Xin Lu,Eun-Jung Jin,Eun-Jung Jin,Xi Cheng,Xi Cheng,Shan Feng,Shan Feng,Xiaoying Shang,Pingna Deng,Shan Jiang,Qing Chang,Sharif Rahmy,Seema Chaudhary,Xuemin Lu,Ren Zhao,Y. Alan Wang,Ronald A. DePinho +18 more
- 01 Dec 2017
TL;DR: In this paper, the authors dissected the roles of TGFβ receptor II (TGFBR2) and BMPR2 (BMPR2) using a Pten-null prostate cancer model.
14
An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer
Xin Lu,Xin Lu,Xin Lu,Xiaolu Pan,Chang-Jiun Wu,Di Zhao,Shan Feng,Yong Zang,Rumi Lee,Sunada Khadka,Samirkumar B. Amin,Eun-Jung Jin,Xiaoying Shang,Pingna Deng,Yanting Luo,William R. Morgenlander,Jacqueline Weinrich,Xuemin Lu,Shan Jiang,Qing Chang,Nora M. Navone,Patricia Troncoso,Ronald A. DePinho,Y. Alan Wang +23 more
- 15 Jul 2018
TL;DR: In this article, the Pygopus family PHD finger 2 (PYGO2) was identified as a driver oncogene in the 1q21.3 amplicon and may serve as a potential biomarker and therapeutic target for metastatic prostate cancer.
6